JP2017537141A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537141A5 JP2017537141A5 JP2017540551A JP2017540551A JP2017537141A5 JP 2017537141 A5 JP2017537141 A5 JP 2017537141A5 JP 2017540551 A JP2017540551 A JP 2017540551A JP 2017540551 A JP2017540551 A JP 2017540551A JP 2017537141 A5 JP2017537141 A5 JP 2017537141A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- seq
- sequence number
- amino acid
- peptide according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 23
- 238000000034 method Methods 0.000 claims 10
- 238000002659 cell therapy Methods 0.000 claims 8
- 150000001413 amino acids Chemical group 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 4
- -1 anthracyclines Chemical class 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 4
- 230000002519 immonomodulatory effect Effects 0.000 claims 3
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 claims 2
- 108010006654 Bleomycin Proteins 0.000 claims 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 claims 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 2
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 2
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims 2
- 239000002145 L01XE14 - Bosutinib Substances 0.000 claims 2
- 239000002146 L01XE16 - Crizotinib Substances 0.000 claims 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 2
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims 2
- 229940028652 abraxane Drugs 0.000 claims 2
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 2
- 229960000397 bevacizumab Drugs 0.000 claims 2
- 229960001561 bleomycin Drugs 0.000 claims 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 2
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 claims 2
- 229960003736 bosutinib Drugs 0.000 claims 2
- 229960004562 carboplatin Drugs 0.000 claims 2
- 190000008236 carboplatin Chemical compound 0.000 claims 2
- 229960001602 ceritinib Drugs 0.000 claims 2
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 claims 2
- 230000000973 chemotherapeutic effect Effects 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 claims 2
- 229960005061 crizotinib Drugs 0.000 claims 2
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 claims 2
- 229960002448 dasatinib Drugs 0.000 claims 2
- 229960003668 docetaxel Drugs 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 2
- 229960001433 erlotinib Drugs 0.000 claims 2
- 229960005167 everolimus Drugs 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 2
- 229960002584 gefitinib Drugs 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 2
- 229960002411 imatinib Drugs 0.000 claims 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 2
- 229960004891 lapatinib Drugs 0.000 claims 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 2
- 229950008325 levothyroxine Drugs 0.000 claims 2
- 229960000485 methotrexate Drugs 0.000 claims 2
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims 2
- 229960001346 nilotinib Drugs 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 229960005079 pemetrexed Drugs 0.000 claims 2
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 2
- 229960004618 prednisone Drugs 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 229960000235 temsirolimus Drugs 0.000 claims 2
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims 2
- 229940036555 thyroid hormone Drugs 0.000 claims 2
- 239000005495 thyroid hormone Substances 0.000 claims 2
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 claims 2
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims 2
- 229960004066 trametinib Drugs 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 claims 1
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 claims 1
- 108091058560 IL8 Proteins 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 102100020881 Interleukin-1 alpha Human genes 0.000 claims 1
- 102000013462 Interleukin-12 Human genes 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 102100033461 Interleukin-17A Human genes 0.000 claims 1
- 102000013264 Interleukin-23 Human genes 0.000 claims 1
- 108010065637 Interleukin-23 Proteins 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 102000004890 Interleukin-8 Human genes 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 claims 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010050207 Skin fibrosis Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 230000005865 ionizing radiation Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 206010023332 keratitis Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462063909P | 2014-10-14 | 2014-10-14 | |
| US62/063,909 | 2014-10-14 | ||
| PCT/US2015/055380 WO2016061133A1 (en) | 2014-10-14 | 2015-10-13 | Peptides having anti-inflammatory properties |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020118752A Division JP2020180149A (ja) | 2014-10-14 | 2020-07-09 | 抗炎症性組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017537141A JP2017537141A (ja) | 2017-12-14 |
| JP2017537141A5 true JP2017537141A5 (enExample) | 2018-11-22 |
| JP7023709B2 JP7023709B2 (ja) | 2022-02-22 |
Family
ID=54365375
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017540549A Expired - Fee Related JP6613312B2 (ja) | 2014-10-14 | 2015-10-13 | 膵臓癌を処置するためのペプチドをベースとする方法 |
| JP2017540551A Active JP7023709B2 (ja) | 2014-10-14 | 2015-10-13 | 抗炎症特性を有するペプチド |
| JP2020118752A Pending JP2020180149A (ja) | 2014-10-14 | 2020-07-09 | 抗炎症性組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017540549A Expired - Fee Related JP6613312B2 (ja) | 2014-10-14 | 2015-10-13 | 膵臓癌を処置するためのペプチドをベースとする方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020118752A Pending JP2020180149A (ja) | 2014-10-14 | 2020-07-09 | 抗炎症性組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US10016480B2 (enExample) |
| EP (2) | EP3206704B1 (enExample) |
| JP (3) | JP6613312B2 (enExample) |
| KR (3) | KR20230004907A (enExample) |
| CN (2) | CN107580502B (enExample) |
| AU (2) | AU2015333678B2 (enExample) |
| BR (1) | BR112017007543A2 (enExample) |
| CA (2) | CA2964361A1 (enExample) |
| WO (2) | WO2016061087A1 (enExample) |
| ZA (1) | ZA201702537B (enExample) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| KR20230004907A (ko) * | 2014-10-14 | 2023-01-06 | 립타이드 바이오사이언스, 인코포레이티드 | 항-염증 특성을 갖는 펩타이드 |
| WO2017149012A1 (en) * | 2016-03-02 | 2017-09-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Peptides and uses thereof for reducing cd95-mediated cell motility |
| CN109563521A (zh) * | 2016-03-24 | 2019-04-02 | 河谷细胞有限公司 | 用于新表位呈递的序列排列和序列 |
| CA3019835A1 (en) | 2016-04-08 | 2017-10-12 | Purdue Research Foundation | Methods and compositions for car t cell therapy |
| CA3023802C (en) | 2016-05-10 | 2025-02-04 | Inserm (Institut De La Sante Et De La Recherche Medicale) | ACTIVATING AGENTS OF THE DIFFERENTIATION CLUSTER 47 FOR USE IN THE TREATMENT OF INFLAMMATION |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| SG11201811074RA (en) | 2016-06-30 | 2019-01-30 | Nant Holdings Ip Llc | Nant cancer vaccine |
| CN106432014B (zh) * | 2016-09-05 | 2019-08-16 | 中国医学科学院放射医学研究所 | 胺基硫醇类化合物及其制备方法和其在辐射防护中的应用 |
| US10799555B2 (en) | 2016-09-15 | 2020-10-13 | Leidos, Inc. | PD-1 peptide inhibitors |
| WO2018086562A1 (en) * | 2016-11-09 | 2018-05-17 | Shen Tang Long | Method for treatment or prevention of cancer |
| US20190358263A1 (en) * | 2016-12-07 | 2019-11-28 | Oslo Universitetssykehus Hf | Compositions and Methods for Cell Therapy |
| US11649288B2 (en) | 2017-02-07 | 2023-05-16 | Seattle Children's Hospital | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| US11850262B2 (en) | 2017-02-28 | 2023-12-26 | Purdue Research Foundation | Compositions and methods for CAR T cell therapy |
| CN110753555A (zh) | 2017-04-19 | 2020-02-04 | 得克萨斯州大学系统董事会 | 表达工程化抗原受体的免疫细胞 |
| IL270132B2 (en) | 2017-04-24 | 2024-12-01 | Nantcell Inc | Neoepitope vectors and methods for them |
| US20190224275A1 (en) | 2017-05-12 | 2019-07-25 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
| WO2018218137A1 (en) | 2017-05-25 | 2018-11-29 | Leidos, Inc. | Pd-1 and ctla-4 dual inhibitor peptides |
| WO2019067984A2 (en) | 2017-09-29 | 2019-04-04 | Sanford Burnham Prebys Medical Discovery Institute | COMPOSITIONS TARGETING TUMOR ASSOCIATED MACROPHAGES AND METHODS OF USING THE SAME |
| CN109745324A (zh) * | 2017-11-06 | 2019-05-14 | 中国科学院上海生命科学研究院 | 非经典NF-kB通路的小分子抑制剂及其应用 |
| CN120154716A (zh) | 2018-01-22 | 2025-06-17 | 恩多塞特公司 | Car t细胞的使用方法 |
| JP7774961B2 (ja) | 2018-02-06 | 2025-11-25 | シアトル チルドレンズ ホスピタル ディー／ビー／エイ シアトル チルドレンズ リサーチ インスティテュート | フルオレセイン結合エーテルリン脂質（ｆｌ－ｐｌｅ）で標識された腫瘍に対して最適なｔ細胞機能を示すフルオレセイン特異的ｃａｒ |
| EP3755349A4 (en) | 2018-02-21 | 2021-11-17 | Board of Regents, The University of Texas System | PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES |
| CA3091674A1 (en) | 2018-02-23 | 2019-08-29 | Endocyte, Inc. | Sequencing method for car t cell therapy |
| AU2018410849B2 (en) | 2018-02-27 | 2025-02-27 | Leidos, Inc. | PD-1 peptide inhibitors |
| US11823773B2 (en) | 2018-04-13 | 2023-11-21 | Nant Holdings Ip, Llc | Nant cancer vaccine strategies |
| EP3810278A1 (en) * | 2018-06-20 | 2021-04-28 | Universidade de Coimbra | (3s)- and (3r)-6,7-bis(hydroxymethyl)-1h,3h-pyrrolo[1,2-c]thiazoles as p53 activators |
| BR112021005464A2 (pt) * | 2018-08-15 | 2021-06-29 | The Regents Of The University Of California | inibição de il-10 para vacinas e imunoterapia |
| WO2020046835A1 (en) * | 2018-08-27 | 2020-03-05 | Nantbio, Inc. | Rp182 compositions and methods |
| CN113039194A (zh) * | 2018-08-29 | 2021-06-25 | 激流生物科学有限公司 | 具有免疫调节特性的肽 |
| US10413584B1 (en) * | 2018-08-29 | 2019-09-17 | Riptide Bioscience, Inc. | Peptides having immunomodulatory properties |
| US20220143130A1 (en) * | 2018-08-29 | 2022-05-12 | Riptide Bioscience, Inc. | Peptides Having Immunomodulatory Properties |
| CN110960679A (zh) * | 2018-09-28 | 2020-04-07 | 江苏康缘药业股份有限公司 | 一种抗肿瘤的药物组合物及其应用 |
| US20220053773A1 (en) * | 2018-10-01 | 2022-02-24 | Innate Immunity LLC | Compositions and methods for the treatment of pathogenic infections in plants |
| US20200102356A1 (en) * | 2018-10-01 | 2020-04-02 | NMC Inc. | Compositions and Methods for the Treatment of Huanglongbing (HLB) aka Citrus Greening in Citrus Plants |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| US10548944B1 (en) | 2018-10-19 | 2020-02-04 | Riptide Bioscience, Inc. | Antimicrobial peptides and methods of using the same |
| WO2020176478A1 (en) | 2019-02-25 | 2020-09-03 | The University Of Chicago | Methods and compositions for treating inflammatory and autoimmune conditions with ecm-affinity peptides linked to anti-inflammatory agents |
| JP2022527133A (ja) * | 2019-04-12 | 2022-05-30 | リップタイド バイオサイエンス インコーポレイテッド | マクロファージの活性を調節する方法 |
| JP7606471B2 (ja) | 2019-05-22 | 2024-12-25 | レイドス， インコーポレイテッド | Ｌａｇ３結合ペプチド |
| CN114051413A (zh) * | 2019-06-28 | 2022-02-15 | 河谷细胞有限公司 | 增强吞噬作用而不引起炎症的药物组合物 |
| CA3165339A1 (en) | 2019-12-19 | 2021-06-24 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Cd206 modulators their use and methods for preparation |
| CN111116713B (zh) * | 2020-01-07 | 2023-06-23 | 郑州大学 | Sirpa蛋白亲和环肽及其应用 |
| AU2021246017A1 (en) * | 2020-03-31 | 2022-11-10 | Innate Immunity LLC | Recombinant peptide to treat fire blight |
| EP4161952A1 (en) | 2020-06-04 | 2023-04-12 | Leidos, Inc. | Immunomodulatory compounds |
| WO2022034523A1 (en) | 2020-08-13 | 2022-02-17 | Immunitybio, Inc. | Phagocytosis-inducing compounds and methods of use |
| US11987646B2 (en) | 2020-10-12 | 2024-05-21 | Leidos, Inc. | Immunomodulatory peptides |
| WO2023277514A1 (ko) * | 2021-06-28 | 2023-01-05 | 고려대학교 산학협력단 | 항암 활성을 갖는 펩타이드 및 이의 용도 |
| CN115607674B (zh) * | 2021-07-15 | 2023-09-19 | 深圳开悦生命科技有限公司 | Rna解旋酶dhx33抑制剂在制备用于治疗胰腺癌的药物中的应用 |
| WO2023080578A1 (ko) * | 2021-11-05 | 2023-05-11 | 주식회사 레메디 | 상처 치료 및 항염증 활성을 가지는 펩타이드 및 이의 용도 |
| WO2023097111A2 (en) * | 2021-11-29 | 2023-06-01 | Riptide Bioscience, Inc. | Methods and compositions for treating calcinosis associated conditions |
| WO2023111695A1 (en) * | 2021-12-16 | 2023-06-22 | Ramakrishna Reddy Isanaka | A stable anti-angiogenic and anti-inflammatory pharmaceutical formulation and pharmaceutical combination for treatment and prevention of psoriasis |
| WO2024102993A1 (en) * | 2022-11-10 | 2024-05-16 | Research Foundation Of The City University Of New York | Cationically-enframed high density aromatic peptides |
| CN115838395A (zh) * | 2022-11-15 | 2023-03-24 | 西北农林科技大学 | 具有可溶性环氧化物水解酶抑制作用的活性肽及其应用 |
| CN116768970A (zh) * | 2023-05-19 | 2023-09-19 | 重庆师范大学 | 抗氧化多肽、制备方法及其应用 |
| CN117143183B (zh) * | 2023-08-25 | 2024-08-16 | 广州益养生物科技有限公司 | 一种三肽、三肽盐或衍生物及其应用 |
| WO2025093952A1 (en) * | 2023-10-30 | 2025-05-08 | Ramakrishna Reddy Isanaka | Peptide with anti-inflammatory and anti-microbial activity |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3854476T2 (de) | 1987-07-06 | 1996-04-04 | Univ Louisiana State | Inhibierung von eukaryotischen pathogenen und neoplasmen mit lytischen peptiden. |
| US5861478A (en) | 1987-07-06 | 1999-01-19 | Helix Biomedix, Inc. | Lytic peptides |
| DE69033436T2 (de) | 1989-04-10 | 2000-06-21 | Helix Biomedix, Inc. | Lytische peptide, verwendung als wachstumsfördernde mittel und für infektionen und krebs |
| AU2514592A (en) * | 1991-08-21 | 1993-03-16 | Board Of Regents, The University Of Texas System | Methods and compositions for modulating g protein action |
| US5955573A (en) * | 1993-06-04 | 1999-09-21 | Demegen, Inc. | Ubiquitin-lytic peptide fusion gene constructs, protein products deriving therefrom, and methods of making and using same |
| US5561107A (en) * | 1993-06-04 | 1996-10-01 | Demeter Biotechnologies, Ltd. | Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo, utilizing amphipathic peptides |
| WO1995013085A1 (en) | 1993-11-08 | 1995-05-18 | Demeter Biotechnologies Ltd. | Methylated lysine-rich lytic peptides and method of making same by reductive alkylation |
| IL114697A0 (en) * | 1994-07-22 | 1995-11-27 | Demeter Biotech Ltd | Polypeptides comprising ubiquitin-lytic peptide fusion protein products deriving therefrom their preparation and use |
| US6514692B2 (en) | 1996-10-04 | 2003-02-04 | Demegen, Inc. | Method for treatment of immunodeficiency virus infection |
| DE19711831C2 (de) | 1997-03-21 | 2000-07-13 | Daimler Chrysler Ag | Schmelzinfiltrierte faserverstärkte Verbundkeramik und Verfahren zur Herstellung einer solchen |
| US6635740B1 (en) | 1997-03-27 | 2003-10-21 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Ligand/lytic peptide compositions and methods of use |
| AU6587998A (en) * | 1997-03-27 | 1998-10-20 | Demeter Biotechnologies, Ltd. | Ligand/lytic peptide compositions and methods of use |
| IL147970A0 (en) * | 1999-08-09 | 2002-09-12 | Tripep Ab | Pharmaceutical compositions containing tripeptides |
| ES2389285T3 (es) | 2001-03-28 | 2012-10-24 | Helix Biomedix, Inc. | Péptidos bioactivos cortos y procedimientos para su uso |
| US7091185B2 (en) | 2003-02-24 | 2006-08-15 | Dow Global Technologies Inc. | Periodic antimicrobial peptides |
| GB0326393D0 (en) | 2003-11-12 | 2003-12-17 | Ares Trading Sa | Cytokine antagonist molecules |
| US7288622B1 (en) | 2006-09-19 | 2007-10-30 | Issar Pharmaceuticals Pvt Ltd | Composition for treatment of burns and wounds |
| US7803755B2 (en) * | 2006-12-21 | 2010-09-28 | Jesse Jaynes | Molecules for the treatment and prevention of fungal diseases |
| TWI436775B (zh) * | 2007-08-24 | 2014-05-11 | Oncotherapy Science Inc | 以抗原胜肽合併化療藥劑治療胰臟癌 |
| CN101485885B (zh) * | 2009-01-09 | 2012-06-27 | 中国科学院广州生物医药与健康研究院 | 蛋白磷酸酯酶PPM1E作为疾病的治疗靶标及其应用和siRNA |
| GB0916576D0 (en) * | 2009-09-22 | 2009-10-28 | Malmsten Nils M | Polypeptides and uses thereof |
| US20120270770A1 (en) * | 2010-08-03 | 2012-10-25 | Jesse Michael Jaynes | Anti-angiogenic peptides and their uses |
| WO2012050892A2 (en) * | 2010-09-29 | 2012-04-19 | Esperance Pharmaceuticals, Inc. | Methods for stimulating, increasing or enhancing killing of a cell that expresses luteinizing hormone releasing hormone (lhrh) receptors |
| US8734775B2 (en) | 2011-08-26 | 2014-05-27 | University Of Pittsburgh | Chemokine derived peptides that bind with chemokine receptor CXCR3 and uses for chronic wound and angiogenesis inhibition treatments |
| US9487560B2 (en) | 2013-05-02 | 2016-11-08 | ISSAR Pharmaceuticals Ltd | Angiogenic active lytic peptides |
| KR20230004907A (ko) * | 2014-10-14 | 2023-01-06 | 립타이드 바이오사이언스, 인코포레이티드 | 항-염증 특성을 갖는 펩타이드 |
| US9737584B2 (en) * | 2015-08-11 | 2017-08-22 | Issar Pharmaceuticals | Composition for the treatment of burns, diabetic wounds, other types of wounds and subsequently greatly reduced scarring |
-
2015
- 2015-10-13 KR KR1020227043575A patent/KR20230004907A/ko not_active Ceased
- 2015-10-13 EP EP15851584.1A patent/EP3206704B1/en active Active
- 2015-10-13 AU AU2015333678A patent/AU2015333678B2/en active Active
- 2015-10-13 KR KR1020177012656A patent/KR20170078689A/ko not_active Ceased
- 2015-10-13 WO PCT/US2015/055305 patent/WO2016061087A1/en not_active Ceased
- 2015-10-13 US US15/518,216 patent/US10016480B2/en active Active
- 2015-10-13 JP JP2017540549A patent/JP6613312B2/ja not_active Expired - Fee Related
- 2015-10-13 CN CN201580067961.7A patent/CN107580502B/zh not_active Expired - Fee Related
- 2015-10-13 EP EP15788259.8A patent/EP3206703B1/en active Active
- 2015-10-13 CA CA2964361A patent/CA2964361A1/en active Pending
- 2015-10-13 AU AU2015333728A patent/AU2015333728B2/en not_active Ceased
- 2015-10-13 KR KR1020177012890A patent/KR102478073B1/ko active Active
- 2015-10-13 WO PCT/US2015/055380 patent/WO2016061133A1/en not_active Ceased
- 2015-10-13 US US14/882,293 patent/US9492499B2/en active Active
- 2015-10-13 CA CA2963478A patent/CA2963478A1/en active Pending
- 2015-10-13 CN CN201580067933.5A patent/CN107106638A/zh active Pending
- 2015-10-13 JP JP2017540551A patent/JP7023709B2/ja active Active
- 2015-10-13 BR BR112017007543A patent/BR112017007543A2/pt not_active Application Discontinuation
-
2016
- 2016-10-05 US US15/286,491 patent/US10149886B2/en active Active
-
2017
- 2017-04-10 ZA ZA2017/02537A patent/ZA201702537B/en unknown
-
2018
- 2018-10-24 US US16/169,819 patent/US20190046601A1/en not_active Abandoned
-
2020
- 2020-07-09 JP JP2020118752A patent/JP2020180149A/ja active Pending
- 2020-09-22 US US17/028,662 patent/US20210077566A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537141A5 (enExample) | ||
| Bello-Rivero et al. | HeberFERON, a new formulation of IFNs with improved pharmacodynamics: Perspective for cancer treatment | |
| JP2022097596A5 (enExample) | ||
| JP2011522834A5 (enExample) | ||
| RU2010154092A (ru) | Применение пэгилированных интерферонов типа iii для лечения гепатита с | |
| WO2016154621A1 (en) | SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF | |
| JP2011527579A5 (enExample) | ||
| JP2016065094A5 (enExample) | ||
| JP2020510662A5 (enExample) | ||
| JP2022009683A (ja) | テノホビルアラフェナミドの結晶形態 | |
| JP2016527286A5 (enExample) | ||
| JP2008507536A5 (enExample) | ||
| JP2013067645A5 (enExample) | ||
| JP2019534891A5 (enExample) | ||
| JP2019526528A5 (enExample) | ||
| EP4186519A1 (en) | Interferon-based cancer treatment method and pharmaceutical composition | |
| JP2017523781A5 (enExample) | ||
| JP2015172060A5 (enExample) | ||
| Marafini et al. | Antisense approach to inflammatory bowel disease: prospects and challenges | |
| CN114224889A (zh) | 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用 | |
| JP2019527676A5 (enExample) | ||
| Mutlu et al. | Rationale, current state and opportunities in combining biologic disease modifying antirheumatic drugs in rheumatoid and psoriatic arthritis | |
| US20210315991A1 (en) | Combination including a cpg-c type oligonucleotide and a pd-1 antagonist for treating breast cancer | |
| EP3215193B1 (en) | Dosage regimen for pegylated interferon | |
| JP2020517671A5 (enExample) |